Efficacy of ICI Rechallenge With Nivolumab or Nivolumab–Ipilimumab Combination in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
J Oncol 2022 Mar 01;[EPub Ahead of Print], C Vauchier, E Auclin, P Barthélémy, L Carril-Ajuria, T Ryckewaert, D Borchiellini, Z Castel-Ajgal, M Bennamoun, L Campedel, A Thiery-Vuillemin, E Coquan, L Crouzet, JF Berdah, C Chevreau, R Ratta, A Fléchon, F Lefort, L Albiges, M Gross-Goupil, YA Vano, C Thibault, S OudardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.